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                                                            INTRODUCTION 
Drug reactions are often under reported and majority of drug reactions are 
minor. Some cases of adverse drug reactions may be major events like 
hepatotoxicity or nephrotoxicity. DILI is one of the leading causes of acute liver 
failure in the US, accounting for 13% of cases of acute liver failure; these 
events pose a major challenge for drug development and safety. Antimicrobials 
and agents for the central nervous system are the most common causes of DILI 
and health foods or dietary supplements account for 7% of cases of DILI in the 
US. In India and other developing countries, ATT is the most important drug 
implicated in DILI .AntiTuberculous drug induced liver injury is mostly due to 
inadequate evaluation of risk factors and “inappropriate dosing”. Worldwide, 
incidence of Anti Tuberculous DILI, between 5 to 33% . This wide variation 
may be due to the predilection of TB towards developing count 1ries than West.  
Even developed nations have a recent surge after the global HIV pandemic of 
HIV during 80s.  In India, a nation contributing significant proportion of TB 
cases, the incidence of ATT DILI ranges between 33 to 35%. In India, 
Approximately 60% of all DILI cases are due to DILI and 70% cases are ATT 
induced Acute Liver Failure. (DIALF)  
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There are studies about risk factors and predisposing factors for DILI. But there 
are only few studies about the frequency of monitoring LFT in patients with 
these risk factors. WHO , which has put monumental effort in eradicating TB ,  
says ,frequent LFT monitoring in all cases are  far from reality due to financial 
drawbacks.  The pathogenesis of DILI and contributory factors and mechanisms 
are not well established till now.  
DILI may occur in all currently recommended regimes for treatment of TB. 
Pyrazinamide, INH, followed by Rifampicin in order, are the most common 
drugs causing DILI. DILI is most common among first line ATT drugs INH, PZ 
and Rifampicin, and the order of DILI with these drugs are also the same in 
decreasing order. Pyrazinamide with rifampicin appears more toxic than INH 
alone. 
Alcoholics with baseline minor elevations of enzymes have to be closely 
monitored. Other patients who need close monitoring are underlying chronic 
liver disease like NASH, concomitant hepatotoxic drugs, other systemic 
diseases like autoimmune diseases, esp. SLE, or metabolic diseases. Patients 
with undiagnosed Chronic hepatitis B or chronic hepatitis C need complete 
evaluation, with  viral load, Hepatitis B’e’ Antigen status, frequent LFTs, extent 
of fibrosis once diagnosed with HBsAg or Anti HCV positivity on screening.  
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Age, sex, comorbid illness, nutritional status, socioeconomic status, literacy, 
staff education, infrastructure, available lab resources and other possible 
confounding factors play a statistically significant role.  
Careful patient selection, adequate basic screening for underlying liver diseases, 
careful selection of regime according to underlying risk factors   and appropriate 
follow up may reduce serious DILI. 
A patient with underlying liver disease, need safer regimes and frequent 
monitoring. This is based on the prognostic scores of the underlying liver 
disease.  
When values of liver enzymes reach critical levels, withdrawal of all 
hepatotoxic drugs, is the most important step in preventing serious Drug 
Induced Acute Liver failure. 
Screening for risk factors, based on the epidemiology, endemicity and 
prevalence of disease may help avoid unnecessary elaborate investigations.  
Screening for chronic viral hepatitis in risk groups, according to the endemic 
prevalence and region wise   investigation   panels may help overcome the 
financial constraints in applying all these tests. Anti-tuberculosis therapy is the 
commonest type of acute liver failure   in South Asia followed by Hepatitis B 
related Acute Liver Failure and alcohol related Acute Liver Failure 
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                                                             REVIEW OF LITERATURE 
Drug induced Liver Injury has been described as ‘’PENALTY FOR PROGRESS”  
.  By Popper and Colleagues’ about 50 years ago. Drug induced liver injury is 
the one of the major cause for the  drawl of drugs prescribed for major illness 
treatment   and is also for withdrawal of drug from the market. A few drugs 
have been withdrawn and banned due to major adverse events. Hepatotoxicity 
constitutes one of major adverse effects due to drugs. There is a unique 
susceptibility of certain individuals to DILI called as idiosyncratic DILI. 
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DILI occurs mostly due to antimicrobials and ATT is one of the significant drugs, 
followed by Amoxicillin-clavulanic acid and flucloxacilin1 
DEFINITION 
The definition of DILI  is as follows “Drug-induced liver injury (DILI) is defined as 
a liver injury caused by various medications, herbs, or other xenobiotic, leading 
to abnormalities in liver tests or liver dysfunction with the reasonable 
exclusion of other aetiologies”.  
Global burden of tuberculosis reduced by ATT: 
With the huge number patients being treated world-wide the safety of ATT 
drugs are placed on a large scale.  
“Global TB reports 2013 by WHO ‘’ has stated that 56 million patients have 
been cured of TB from 1995 to 20122.  The path to eradicate TB is still under 
way and treating any newly diagnosed TB by ATT is an economic 
emergency,3. Treating TB with the drugs available, over a period of 6 to 9 
months has still been a double edged sword in patients with proven risk factors 
for DILI.  
ATT and hepatotoxicity – “The double edged sword”:   
In a study done by S.K.Acharya, Shalimar and Vikram Bhatia, “Anti tuberculosis 
Therapy–Induced Acute Liver Failure: Magnitude, Proﬁle, Prognosis, and 
Predictors of Outcome, Hepatology, May 2010.4, a meta-analysis ‘’it is 
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concluded that the “frequency of overt clinical hepatitis caused by isoniazid, 
rifampicin, or both together was 0.6%, 1.1%, and 2.6%, respectively”.   
 
 
Anti-tuberculous drugs are the most important cause of acute liver failure, 
especially in developing countries. Endemicity of locally prevalent diseases, 
decide the other causes of acute liver failure 5. In west ,acetaminophen is the 
important cause for drug induced Acute liver failure. While in South Asia and 
South East Asia ,Acute viral Hepatitis are the other leading causes along with 
ATT DILI. Most studies in Acute Liver failure from Asia Pacific disclose Acute 
Hepatitis B as commonest cause.  In India , especially in pregnany and 
underlying liver diseases, it is Acute Hepatitis E the cause for fulminant 
hepatitis with acute liver failure6.The incidence of acute liver failure is higher 
when risk factors  are present. 
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 Hepatic Drug Metabolism Transporters, Enzymes, and Excretion: 
The splanchnic circulation carries ingested drugs directly into the liver, a 
phenomenon known as the "first pass" through the liver. 
 Drugs are converted to metabolites by three phases of metabolism in liver.  
 
Phase 1 pathways of oxidation, reduction, or hydrolysis, which are carried out 
principally by the cytochrome p450 class of enzymes.  
 
Phase 2 pathways include glucuronidation, sulfation, acetylation, and 
glutathione conjugation to form compounds that are readily excreted from the 
body. Other subsequent steps include Deacetylation and deamination. Many 
drugs may be metabolized through alternative pathways.  
 
In phase 3 pathways, cellular transporter proteins facilitate excretion of these 
compounds into bile or the systemic circulation. 
 
The production and functioning of these transporters and enzymes are 
influenced by endogenous factors like circadian rhythms, hormones cytokines, 
chronic illness, genetic factors, sex, age, ethnicity and nutritional status, as well 
as by exogenous drugs or chemicals
7
. 
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.  
Pathogenesis of drug-induced   hepatotoxicity:  
This may be result from direct toxicity of the primary compound, a metabolite, 
or from an immunologically mediated response, affecting hepatocytes, biliary 
epithelial cells, or blood vessels. 
 
The exact mechanism contributing to the hepatotoxicity due to drugs is not clear 
yet. 
Parent drugs or their reactive metabolites can cause cell stress to produce 
cytokines, chemokines, ROS, and reactive nitrogen species (RNS) which may 
cause apoptosis or necrosis .The inflammatory mediators released and innate 
immunity may decide the outcome of DILI.
8 
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Mechanism of DILI: 
  
 
 
Mitochondria plays the central role in DILI
9
: 
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Types of DILI: 
DILI may be either dose related or idiosyncratic. Idiosyncratic reactions are one 
of common types of drug injury. These hypersensitivity reactions are not related 
to dosage and duration of drugs
10
. In other words they are unpredictable.  This 
idiosyncrasy may result in hepatocellular injury and or cholestasis.  In 
idiosyncrasy, injurious free radicals cause hepatocyte necrosis in zones farthest 
from the hepatic arterioles, where metabolism is greatest and oxidant 
detoxifying capacity is the least. 
In dose dependant DILI, the injury is intrinsic, and it is predictable .In dose 
dependent DILI hepatocyte necrosis is predominantly distributed throughout 
hepatic lobules rather than zonal. 
 Model of pathogenesis of idiosyncratic DILI: 
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This model shows the mechanism of liver injury when hepatocytes are exposed 
to a critical level of reactive metabolite leading to neoantigen or hapten 
formation and hazardous effects on hepatocytes. Both are needed for 
idiosyncratic DILI. 
Adaptation and immune tolerance dissipates the toxic effect. So, always an 
impaired  
Adaptation may lead to overt injury. Haptens or neoantigens formed by 
immunogenic drugs or its metabolites covalently binding to hepatic proteins, in 
hypersensitive reactions.  Eosinophilic hypersensitivity reactions are provoked 
by Antibody dependent cytotoxic, T-cells. Tumour necrosis factor-alpha, 
interleukin (IL)-12, and IFN gamma are produced and promote hepatocellular 
apoptosis. This apoptosis is opposed by IL-4, IL-10, IL-13, and monocyte 
chemo tactic protein-1
11, 12
.  
MECHANISM OF HEPATOTOXICITY IN ATT: 
1. Isoniazid: 
Normally isoniazid is cleared mostly by the liver, primarily by acetylation by N-
acetyl transferase2 (NAT-2). Acetyl-isoniazid is metabolized mainly to 
monoacetyl
14 
Hydrazine (MAH) and to the no toxic diacetyl hydrazine, as well as other minor 
metabolites. The reactive metabolites of monoacetyl hydrazine (MAH) are 
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probably toxic to tissues through free radical generation. The additional 
isoniazid metabolites acetyl hydrazine covalently binds to liver 
macromolecules, a process mediated by microsomal enzyme.
13, 16 
2. Rifampicin: Rifampicin may occasionally cause dose dependent interference 
with bilirubin uptake resulting in subclinical, unconjugated hyperbilirubinemia 
or jaundice without hepatocellular damage.
15
 Conjugated hyperbilirubinemia 
probably is caused by rifampicin inhibiting the major bile salt exporter pump. 
Asymptomatic elevated bilirubin may also result from dose-depended 
competition with bilirubin for clearance at sinusoidal membrane or from 
impeded secretion at the canalicular level. 
3. Pyrazinamide: It may exhibit both dose dependent and idiosyncratic 
hepatotoxicity. Pyrazinamide alters nicotinamide acetyl dehydrogenase levels in 
liver which might result in generation of free radical species
17
. There may be 
shared mechanisms of injury for isoniazid and pyrazinamide, because there is 
some similarity in molecular structure. Patients who previously had hepatotoxic 
reactions with isoniazid have more severe reaction with rifampicin and 
pyrazinamide
18
. 
4. Ethambutol: There has been one report of ethambutol related liver 
cholestatic jaundice with unclear circumstances
19
. 
 EPIDEMIOLOGY OF ATT DILI:  
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 Hepatitis develops in approximately 21 of 1000 persons exposed to isoniazid; 
5% to 10% of cases are fatal .The risk and severity of isoniazid hepatitis 
increase with age; the risk is 0.3% in the third decade of life and increases to 
2% or higher after age 50  INH toxicity is not dose dependant or with increased 
therapeutic levels. 
Slow acetylators of isoniazid may be at increased risk of toxicity, but the data 
are conflicting. Risk factors: chronic alcohol use, concurrent use of Rifampin, 
pyrazinamide
20
, acetaminophen, HBV, HCV, HIV.  
Serum ALT levels increase in 10% to 36% of persons taking isoniazid during 
the first 10 weeks. Abnormalities typically are minor and resolve spontaneously. 
In persons in whom hepatitis develops, the latent period from exposure to 
disease ranges from 1 week to more than 6 months; the median is approximately 
8 weeks, and 12 weeks for severe cases. 
 The prodromal symptoms occur in one third of patients and include malaise, 
fatigue, and early symptoms of hepatitis such as anorexia, nausea, and vomiting. 
Jaundice appears several days later and is the only feature in approximately 
10% of cases. Most cases with a fatal outcome have been associated with a 
longer duration of therapy or continued ingestion of isoniazid after the onset of 
symptoms. Recovery is rapid if isoniazid is discontinued before severe liver 
injury is established. 
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Other Anti-Tuberculous drugs: 
Most cases in which Rifampicin has been implicated with liver injury have 
occurred in patients taking isoniazid, but a few cases have been observed when 
Rifampicin was given alone to patients with underlying liver disease
21
. 
Pyrazinamide (as well as the related Ethionamide) was known as a dose-
dependent hepatotoxin. Hepatotoxicity may be particularly severe in patients 
taking combinations that include isoniazid and pyrazinamide
22, 23 
Concomitant hepatotoxic drugs: 
They add fuel to the fire. Drugs like methotrexate, chlorpromazine, long term 
acetaminophen, prolonged anti-microbial like fluocloxacillin are proven 
hepatotoxic. In these patients on prolonged hepatotoxic drugs, adding ATT, 
even though with normal baseline LFT results in acute fulminant steatohepatitis, 
or a massive parenchymal necrosis
24,25
 and “HYPERACUTE LIVER 
FAILURE”, in less than 7 days with a short latency and jaundice 
encephalopathy interval. Prognosis is guarded in these patients without an early 
transplant.  
Pattern of DILI:  
Drugs may cause hepatocellular, mixed or cholestatic injury. This calculated by 
the R-value, based on ALT and SAP levels. 
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Cholestatic  Mixed Hepatocellular 
Canalicular , ductular Hepatitis and cholestasis Cytotoxic,       
Parenchymal necrosis, 
Apoptosis. 
 R value <2 Rvalue 2 to 5 Rvalue >5 
 
Causality Assessment of DILI: 
“Percentages of methods for causality assessment in DILI, reported during the 
last decade” in a study done comparing causality assessment methods, shows 
that most cases are not assessed while, RUCAM and CIOMS are the most 
commonly employed methods26. 
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Roussel Uclaf Causality Assessment Method (RUCAM):- 
This is the most widely used. The RUCAM assesses non-organ specific drug reaction 
to well-defined hepatic reactions.  
7 major criteria of RUCAM scale are 
 (1) Time to onset, 
 (2) Course of the reaction, 
 (3) Risk factors for the reaction,  
 (4) Assessing the role of concomitant therapies,  
 (5) Screening for non-drug-related causes, 
 (6) Weighing the information known about the DILI in question,  
 (7) Confirmation of the reaction by positive rechallenge or in vitro assays.  
The grading of casual assessment is as follows: 
Excluded, Unlikely, Possible, Probable, and highly probable. Many studies have 
quoted that “RUCAM assessment should not be taken as the only diagnostic tool. It 
has its suboptimal retest reliability and lack of robust validation, but it is useful in 
providing a diagnostic framework upon which to guide an evaluation in patients with 
suspected DILI”. Causality assessment along with evaluation appears to be the most 
useful way of establishing DILI now, but presently cannot be practised
27
.  
There are various cut off levels used worldwide to stop ATT with onset of DILI 
like WHO Grading, American thoracic society, British thoracic society 
,European Respiratory society and Hong KongTuberculosis society. ‘Stopping 
the drug’ is the most important step in preventing DILI.28  
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DIAGNOSIS OF DILI: 
DILI as such is difficult to diagnose.With each drug being unique in its 
presentation, ruling out other causes might help diagnosing DILI.The most 
common competing etiologies must be in considered before DILI29. 
 
Recently Biomarkers play a role in diagnosing DILI, but are not put in for 
practice. They are still under research. 
Biopsy: The role of biopsy in establishing DILI is still kept at bay, since 
diagnosing DILI, by an invasive method outweighs its fruitfulness. 
Most biopsy, although unique to a drug overlies on the pattern of injury 
produced by the drug. e.g., cholestsatic or hepatocellular. Autoimmune 
hepatitis mimic, is frequent finding encountered in the biopsy specimen for 
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DILI. Biopsy will be gold standard in differentiating other causes from DILI 
,rather than for unique pattern of a drug32. 
Risk factors for susceptibility to drug-induced hepatotoxicity: 
 
Increasing age, underlying undiagnosed liver disease, female gender, low socio 
economic status, lower literacy levels, lack of knowledge, poor staff 
education
30
. 
                  Poor lab infrastructure, poor follow up is one of the most important 
causes for DILI in developing countries. While in western countries HAART     
(Highly Active Anti-Retroviral therapy) may attribute to the added risk of DILI. 
Diabetes and female gender, and other concomitant drugs
31
 add to the risk of 
DILI 
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Severity of DILI: 
Animal model studies, have established the risk of susceptibility to DILI is 
more in Diabetics, although human studies are not available and  
Diabetes has not yet been established as the cause of DILI. 
“A preliminary report from the United States Drug-Induced Liver Injury Network 
(DILIN) showed that  underlying diabetes mellitus was independently associated with 
the severity of DILI (odds ratio = 2 .69; 95%   CI = 1 .14– 6 .45)”   
 
 “Competing Aetiologies and Unmasking DILI”: 
 “Acute hepatitis C and Acute hepatitis E infections are known masquerades’ of DILI” 
as written according to the recent American college of Gastro Enterology Guidelines 
for DILI by Naga N Chalasani. The incidence of Acute Hepatitis C occurring as a 
masquerade of DILI is about 1.3%, in a prospective study by DILI Network. 
Antibodies to Hep C may be initially negative and HEV RNA
33
 also may be negative 
in the acute illness of hepatitis.  DILI ACG guidelines 2014, have recommended   
HCV RNA in suspected DILI. Another published report from the DILIN showed that 
“3 % of individuals with suspected DILI tested positive for anti-hepatitis E Ig M”.  
Hence Hep E IgM is needed while evaluating DILI
34
. 
              The other most important disease to be considered in all causes of DILI 
especially DILI is autoimmune hepatitis
36
.  Autoimmune Hepatitis is an important 
Differential Diagnosis in DILI to be had in mind. Patients may be ordered an 
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autoimmune profile including Antinuclear Antibody, Anti Mitochondrial 
Antibody,
37 
Smooth Muscle Antibody   and Liver Kidney Microsomal Antibody according 
to their clinical presentation, when Autoimmune Hepatitis may be possible 
confounder of DILI. Liver biopsy might be rarely needed when diagnostic 
dilemmas still persist. High level titres often help diagnosing AIH while low 
titres may be found in otherwise asymptomatic females.  
Other aetiologies causing moderate to fulminant hepatitis are Wilson’s disease, 
Herbal and Dietary Supplements. There no confirmatory tests yet for Herbal and 
Dietary supplements induced toxic Hepatitis. A work up for Wilsons may be 
needed based on age, and other clinical features of neurologic or renal 
involvement. In many cases the other system involvement may be subtle. A slit 
lamp examination for KF ring, S.Ceruloplasmin, 24 hour Urinary copper is   
needed in fulminant hepatitis. Treating Wilson’s may prevent   deaths in 
Fulminant Hepatic Failure. ATP B7 gene testing may be needed in difficult to 
diagnose cases, but with strong suspicion of WD. 
 A tender hepatomegaly in acute hepatitis should raise a suspicion of Acute 
Budd Chiarri syndrome. 
Other “Competing aetiologies” in DILI with a cholestatic picture are 
PancreatoBiliary causes; individuals with suspected cholestatic DILI are 
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Pancreato-biliary in nature and can be extrahepatic or intrahepatic. 
Extrahepatic etiologies such as choledocholithiasis or malignancies 
(e.g., pancreatobiliary or lymphoma) can be readily identified with 
abdominal imaging. Other competing aetiologies like Granulomatous hepatitis,  
 
 
Primary biliary cirrhosis, and Primary sclerosing cholangitis must also be considered. 
Last, but not the least, are other aetiologies like sepsis, total parenteral nutrition and 
congestive cardiac failure.  
   Biopsy may not be the “one and all” investigation as in text book descriptions. Each 
drug may have a unique pattern but also may mimic a disease pattern, like cholestatic 
or hepatocellular injury. Few drugs overlap features of auto immune hepatitis. 
More than diagnosing a particular drug pattern, liver biopsy helps rule out other 
causes “i.e., findings beyond DILI”.  
Typically, cholestatic DILI takes longer to resolve than the hepatocellular DILI. 
     There are no prospective studies examining the yield of biopsy. However, 
considering a biopsy at 60 days for unresolved acute hepatocellular and 180 days for 
cholestatic DILI is reasonable.  
MANAGEMENT OF DILI Identifying a drug, by its toxic potential is the most 
important step, in preventing DILI. “Compound selection and heightened vigilance in 
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developing speciﬁc agents to identify which chemical entities are entirely safe” with 
animal testing and other rigorous methods are the most important steps in drug 
development. The reasons include differences in metabolic pathways of drug handling 
and the current lack of suitable animal models that reproduce the human risk factors. 
But, except acetaminophen, most drugs are idiosyncratic and hence behave in an 
unpredictable way .One study has revealed the pre-determined genetic polymorphisms 
in major histocompatibility complex (MHC) Class I and II genes in the pathogenesis 
of IDILI.  
In ATT induced severe DILI, discontinuation of PZ and INH, make improvement in 
50% cases. 
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ATT and altered Baseline LFT values: 
With the prevalence of alcoholism and diabetes more in developing countries, a 
significant proportion of patients have baseline altered LFT values. There are no                 
clear cut evidence-based guidelines exist for the use prescribing ATT, in patients with 
cirrhosis. When no other alternatives are advisable, close monitoring is needed. Risk 
factors should also be evaluated. Patients. In alcoholics and cirrhosis, ATT is 
associated with hepatotoxicity in 10%. “Recommended ATT in Child class A cirrhosis 
is the same as a noncirrhotic population but strict follow up is required. In Child class 
B Pyrazinamide should be avoided”. Isoniazid and rifampicin may be avoided. 
Medications should be individualized depending upon various factors. Surveillance 
using liver enzymes though recommended routinely the use of INH can lead to acute 
liver failure despite the surveillance.  
The cause for the underlying liver enzyme abnormality or the liver disease must be 
established before starting ATT. 
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Guidelines for management of ATT induced liver injury, Baljit Ahitan, Approved by ID & 
Resp Directorates ,July 2013. NHS foundation.  
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Guidelines for management of ATT induced liver injury, Baljit Ahitan, Approved by ID & 
Resp Directorates ,July 2013. NHS foundation.  
 
Hepatotoxicity requires withdrawal, modiﬁcation and sequential reintroduction 
to achieve cure of tuberculosis In conclusion, acute liver failure is a serious 
complication of ATT. Monitoring of liver function parameters at regular 
intervals can help to prevent this condition . 
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Medical management: 
With varied ways of presentation, DILI is unpredictable, with a very short 
latency period and very short Jaundice Encephalopathy interval. A few carry a 
hyper acute course and high 7 day mortality. Some have fulminant course as, 
Fulminant liver failure. Cases with underlying chronic liver disease, have 
“golden therapeutic window” over worsening in few days and not weeks.(aclf-
acute on chronic liver failure). Given below are the alternative drugs, given 
instead non Hepatotoxics 
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Acute on chronic liver failure: Acute insult in a patient with low hepatic 
reserve by drugs, in underlying chronic liver disease , leading to acute on 
chronic failure, with a high short term mortality.   
 
 
 
 
 
 
 
 
37 
 
      
Intervening in the golden therapeutic window prevents 
ALF mortality  
 
Management  of  DILI   WITH  CONCOMITANT  HAART: 
1.Intensive phase of TB  Treatment 
  Mild DILI: Clinically well with elevated ALT 
 <200 IU/l and total bilirubin <40 μmol/l 
 
• Continue TB drugs in the event of confirmed or probable TB. 
• Continue ART if the patient is receiving ART. 
• Repeat ALT and bilirubin in one week. 
 
 
38 
 
• If ALT and bilirubin have improved or normalised, stop laboratory 
Monitoring. 
• If ALT and bilirubin remain elevated but stable for 4 consecutive 
weeks, consider the other causes listed above, abdominal sonar and 
referral for further workup of liver dysfunction. 
• If ALT and bilirubin increase further and meet the DILI definition, 
then move on to the relevant section below. 
 
6.1.2 Moderate DILI: Clinically well and elevated ALT 
>200 IU/l irrespective of total bilirubin 
 
• Discontinue the standard TB regimen. 
• Start STR, moxifloxacin (MOX) and EMB  
• Discontinue co-trimoxazole prophylaxis and other hepatotoxic drugs. 
 If the patient is on a PI-based regimen, stop all drugs at once. If the patient has      
  been on a stable ART regimen for >6 months, consider continuing the therapy, 
  as it is less likely that ART is the cause. 
• Repeat ALT and bilirubin in 2 - 3 (inpatient) or 7 days (outpatient). 
• When ALT is <100 IU/l and total bilirubin is normal, start the rechallenge. 
• Day 1: RIF 450 or 600 mg daily, depending on weight. 
• Day 3: Check ALT. 
• Day 4 - 6: Add 300 mg INH daily. 
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American college of Gastro enterology Guidelines ,2014                                
for evaluating DILI. 
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                                                 AIM OF THE STUDY 
 
 
Primary Aim: 
1. To identify DILI even before onset of symptoms, which may prevent serious 
drug induced Acute Liver failure. 
2. To identify the risk factors for DILI due to Anti Tubercular Treatment. 
3. To formulate the way of monitoring for DILI in patients who are started ATT 
 
Secondary:                   
 
1. To study the Prevalence of ATT DILI in patients with deranged baseline LFT 
values. 
2. To study the Incidence of Hepatic adaptation and its significance in 
monitoring patients on ATT. 
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                       MATERIALS AND METHODS 
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                                                 MATERIALS AND METHODS 
 
This is a prospective study from our Institute, Department of Digestive Health 
and Diseases. Government peripheral Hospital Anna Nagar., a tertiary care 
Centre, fed by a chest clinic and many DOTS (Directly Observed Short Term 
Chemotherapy) centers. 
The study period is from January 2014 to January 2015. 
 
THE STUDY GROUP: 
The Study population is patients who are registered under dots and started on 
ATT, at chest clinic, Govt. Kilpauk medical college. They were patients 
diagnosed with TB, pulmonary or extra pulmonary. Also, they were not on 
previous anti-TB chemotherapy higher than two weeks . 
 
All patients were followed till the end of their ATT COURSE  and LFT was 
monitored. 
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EXCLUSION CRITERIA: 
                                                  1. HIV POSITIVE AND ON HAART,  
                                                  2. PREGNANT FEMALES,   
                                                  3. POSTPARTUM 3 MONTHS,  
                                                  4. PATIENTS ON CANCER CHEMOTHERAPY, 
                                                  5. AGE LESS THAN 18 YEARS 
                                                  6. MORIBOUND STATE 
 
LFT and clinical monitoring in patients  who are selected under the inclusion 
criteria in the study were followed up till the end of their therapy by serial 
LFTs. Patients were divided into two groups according to their baseline LFT           
as follows., 
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1. GROUP 1 –PATIENTS WITH NORMAL BASELINE LFT VALUES 
 
2. GROUP 2- PATIENTS WITH BASELINE ALTERED LFT VALUES 
 
LFT was done baseline and every week for the first month, then fortnightly for 
the next 2 months and then monthly until the end of therapy. Patients with 
clinical and lab evidence of DILI were evaluated for risk factors. 
All results were analysed for both groups. Patients with referred with ATT DILI 
to this tertiary care were analyzed for Risk factors and the Demographic profile 
of DILI. 
Finally the incidence of DILI in both groups was analysed. 
The incidence of hepatic adaptation was analysed 
Also, the mortality rate in patients taking ATT and significance of risk factors 
in, mortality of DILI was analysed. 
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An ATT DILI criterion is taken according to American Thoracic Society 
Guidelines-2006, when any one of these three criteria was met ATT was 
stopped. 
1. S.Transaminases >3 ULN with Symptoms         
2. S.Transaminases >5ULN without Symptoms   
3. Any increase in Bilirubin                                 
 
DILI Grading is according to WHO criteria. 
 
Grading (WHO)Grade ALT 
1 ≤ 2.5x ULN 
2 2.6 –5x ULN 
3 5 –10x ULN 
4 > 10x ULN  
 
Written informed consent was obtained from all participating subjects in 
regional language. Privacy was insured. Statistical analysis was done by 
statistical software SPSS version 22. 
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The outcome measures analysed  were as follows: 
Outcome measures: 
1. Latency 
2. Identification of risk factors for DILI  
3. Role of comorbid illness in DILI  
4. Masquerades’ of DILI   
5. Requirement of hospitalization; 
 6. Severity of liver dysfunction;  
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 7. Outcome of DILI was taken as, 
1. MILD  
2. SEVERE  
3. ACUTE LIVER FAILURE  
4. ACUTE ON CHRONIC LIVER FAILURE  
5. PERSISTANT ENZYME ELEVATION 
 6. RECOVERY  
7. DEATH                                        
8. IMPACT OF ANTI-TB TREATMENT ON OUTCOME OF DISEASE. 
 
 
Patients who developed Liver Injury are assessed according to Roussel Uclaf 
Causality Assessment Method (RUCAM). 
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The 7 major criteria of RUCAM scale are 
 (1) Time to onset, 
 (2) Course of the reaction, 
 (3) Risk factors for the reaction,  
 (4) Assessing the role of concomitant therapies,  
 (5) Screening for non-drug-related causes, 
 (6) Weighing the information known about the DILI in question,  
 (7) Confirmation of the reaction by positive rechallenge or in 
vitro assays  
 
Modification/Re-challenge of ATT is according to guidelines of American 
Thoracic Society, 2006 
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                                            STATISTICAL ANALYSIS 
Data were analysed with SPSS version 1.5. 
Descriptive statistics including mean, median, p value, and frequencies were 
analysed. 
Fisher value was analysed. 
Odds ratio and risk benefit ratio was also analysed. 
Values were considered significant if p<0.05 (95%CI) 
Incidence of DILI in two groups and  recovery or mortality were analysed. 
Frequency distribution of hepatic adaptation was analysed in both groups. 
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                                                                                    RESULTS 
A   total number of   145 patients who were on ATT were enrolled for study. 
Patient with normal baseline LFT values were taken as Group 1.  Patients with 
Altered baseline LFT were taken as Group 2. 
1 patient Defaulted in group 2. 
n=145 GROUP 1 
Normal Baseline LFT 
GROUP 2 
Altered baseline LFT 
No.of cases 116  29  
Males  62 28 
Females 54 1 
Diabetics  14 5 
Age >50 years 33 12 
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1. Study population:  
 Table 1 
n=145 GROUP 1 
Normal Baseline LFT 
GROUP 2 
Altered baseline LFT 
No. of cases 116  29  
 
Group 1 patients were started on conventional   DOTS ATT drugs, according to 
Category of TB. 
 Patients in Group 2 were started on ATT according to their AST, ALT and 
Bilirubin levels.  In cases of Decompensated Chronic Liver Disease, one or two 
hepatotoxic drugs were prescribed according to prognostic scoring Child 
Turcotte Pugh classification as single, or two   hepatotoxic drugs DOTS ATT. 
Other parameters like Albumin, MELD, Prothrombin time, INR were also taken 
into account.   
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2. Gender distribution of study population: 
 
Group 1 had 116 patients, of whom 54 were females and 62 were males. 
Among Group 2, with 29 patients there were 28 males and only one female. 
 
3. Age distribution of cases among group 1 & 2:   
Majority of patients were <50 years of age in Group 1, whereas almost equal in 
Group 2.  
78% were <50years in Group 1 and 58.6% were <50 years in Group2.                                            
 
TABLE 2:  AGE DISTRIBUTION AMONG STUDY   GROUPS: 
Age group Group 1 Group 2 
<50 years 83 (71%) 17 (58.6%) 
≥50 years 33 (29%) 12 (41.3%) 
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4. Concomitant drugs: In Group 1 , all diabetics were on Oral Hypoglycaemic 
Agents  and one patient , a known case of crippling Rheumatoid arthritis was 
on 4 years of Methotrexate, with LFT monitoring. The partient on 
Methotrexate had normal baseline LFT. 
In Group 2, all patients with Decompensated Chronic Liver disease were on 
diuretics and propranolol, Diabetics were on insulin. One Group 2 one patient 
was on long term chlorpromazine >20  years , and he stopped , the drug for 7 
months when he was referred for  Ascites.         
 
 OHAs INSULIN DIURETICS PROPANOLOL OTHERS 
Group 1 14 0 0 0 Methotrexate 
Group 2 0 5 15 15       1- Chlorpromazine 
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5. Causes  of altered baseline LFT values- Group 2 
 
Alcohol  CHB ? Drug related NASH 
24 2 1 2 
82% 6.8% 3.4% 6.% 
 
 
6. Serum albumin levels in group 2 :Since all our patients were in CTP B, the 
Serum Albumin was >2.5 gm/dl in 82% cases. 
 
S.Albumin <2.5 5cases 18% 
S.Albumin >2.5 24cases 82% 
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7.PROFILE  OF CASES -ALTERED BASELINE LFT VALUES, GROUP 2 
Patients had  various causes and stages of liver disease. They were also 
analysed. 
 
 
N= cases 
CTP A DCLD 0 cases 0% 
CTP  - B DCLD 18 62.3% 
CHB related CLD 2 6.8 
? DRUG RELATED CLD 1 3.4 
COMPENSATED LIVER  DISEASE 8 27.5 
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In group 2, a total of 18 patients were in CTP Class B Decompensated Chronic 
Liver Disease irrespective of etiology. 2 patients had compensated chronic liver 
disease due to Chronic Hepatitis B infection. 1 patient had chlorpromazine 
related altered LFT values ? Chronic choleststatic  liver  injury. 
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WHO GRADING OF DILI : 
DILI patients were classified according to WHO criteria for grading of DILI 
according to ALT levels.  
Grading (WHO)Grade ALT 
1 ≤ 2.5x ULN 
2 2.6 –5x ULN 
3 5 –10x ULN 
4 > 10x ULN  
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Grade 1 Grade 2 Grade 3 Grade 4 
ALT<3ULN ALT3-5ULN 5-10 ULN >10ULN 
1 case 4cases 4 cases 2cases 
 
Who grading  DILI 
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1. Incidence of DILI: 
N=cases GROUP 1 GROUP 2 
Total  116 29 
DILI 11 6 
 
The incidence of Drug induced liver injury in Group 1 & 2 Both is 11.7% 
Incidence of DILI in Group 1 is    9.48% 
Incidence of DILI in Group 2 is    20.7% 
                                                                                                                    Figure-1: 
0.00%
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10.00%
15.00%
20.00%
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2. Incidence of DILI Group1  
DILI
AbsentPresent
F
re
qu
e
n
cy
120
100
80
60
40
20
0
                                                   
Incidence of DILI among Group 1, has a statistical significance with p <0.001 
                                      Group 1(n=116)                                                                                                                                                                                    
Non DILI DILI P value 
105 11 0.001 
90.5% 9.4%  
 
 
Patients  with normal baseline LFT had stastically significant incidence 
of DILI of 9.4%(p<0.001) 
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3. Mortality Rate: 
 
a.Mortality due to ATT, among the total study population is 4.1%.(n=145) 
Mortality due to ATT among Group 1 is 2.5%.              
Mortality due to ATT in Group 2 is 10.3% 
Group
Group IIGroup I
C
o
u
n
t
9
8
7
6
5
4
3
2
DILI
Not recoverd
Recovered
 
 
The cause specific mortality rate for Group 1 patients with DILI-27.2% 
The cause specific mortality rate fort Group 2 patients with DILI- 50% 
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4. Mortality in Group 1   
Gender
FemaleMale
C
o
u
n
t
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
.5
DILI
Not recoverd
Recovered
  
a. Mortality rate between male and female in Group 1 and 2 was not   
stastically significant,  
b. But females had a slightly higher incidence of DILI deaths. 
  
Total DILI n=11 Died P value 
Male  5 1 0.621 
Female  6 2  
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5. Mortality rate in Group 2: 
Group
Group IIGroup I
C
o
u
n
t
9
8
7
6
5
4
3
2
DILI
Not recoverd
Recovered
 
 Mortality among Group 2 (n=25) 
 The mortality rate in Patients on ATT in Group 2 is 10.3% 
 
There is stastical significance between patients recovered and not     
recovered in Group 2. (p<0.001) 
DILI Recovered Died  p 
Present  3 3 0.001 
Absent  23 0  
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6. Mortality in females - Group 1 
Females have higher Odds for DILI deaths compared to males.  
  
 
 
n=11 Total DILI  Recovered  Died Odds Ratio 
Male  5 4 1 M/F 0.5 
Female  6 4 2 95%CI (0.31-7.94) 
 
 
Gender
FemaleMale
C
o
u
n
t
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
.5
DILI
Not recoverd
Recovered
 
 
2.Since there were no females died of DILI  in Group 2 , p value and 
odds ratio was not applicable. 
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7. Mortality in Diabetics: 
DM
AbsentPresent
C
o
u
n
t
100
80
60
40
20
0
DILI
Present
Absent
 
 
 
 
DILI DIABETIC NON DIABETIC P VALUE 
Present  2 12 0.425 
Absent  9 93  
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DM
AbsentPresent
C
o
u
n
t
8
7
6
5
4
3
2
1
0
DILI
Not recoverd
Recovered
 
Mortality in Diabetics- Group 1 
 
 Diabetics Non diabetics Odds Ratio 
DILI Recovered  1 2 3.5 
DILI died 1 7 95% CI (0.145 -84.4) 
 
Diabetics have higher Odds in DILI related mortality than Non Diabetics 
in Group 1. 
2. Since there were no diabetics, who died in Group 2,                                 
p  value and Odds ratio was not applicable.  
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8. Hepatic adaptation in Group 1 patients:  
Hepatic adaptation in Group 1 was 6.9%.   
8/116 patients had hepatic adaptation. 
8
106
0
20
40
60
80
100
120
Yes No
Hepatic adaptation - Group 1
cases
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Hepatic Adaptation in Group 2: 
Hepatic adaptation in Group 2 was seen among 14 out of 29 patients. The 
incidence of hepatic adaptation was 48.3% in Group2 
 
 
. 
YES
14
48.3
NO
cases.
29
%
51.67
Hepatic Adaptation - Group 2 
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9. Outcome of DILI -Group 1 
MILD DILI SEVERE DILI  DIALF DIACLF PERSISTANT DILI 
1 4 1 3 2 
All recovered All recovered 1 died 2died. 
1 recovered 
Recovered 
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10. Types of DILI:  Group 1 
TYPE OF DILI NUMBERS REMARKS 
CONVENTIONAL  ATT DILI 4 (3M+1F) 2   DIABETICS  ( ALCOHOLIC) 
UNMASKING DILI 2F 1 -  LUPOID HEPATITIS  +  WILSONS  
1- ?AIH 
FULMINANT HEP E 
MASQUERADING 
1F 1 DIABETIC, DIED 
FULMINANT HEP A 
MASQUERADING 
1M ALCOHOL AND NSAIDS -CONFOUNDING FACTORS 
MTX CUMULATION INDUCED 
ATT HEPATITIS 
1F 4YRS OF MTX  , BUT NORMAL BASAL LFT. 
PERSISITING DILI 2M ?ALCOHOL 
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11. Outcome of DILI -Group 2:    
 
 
MILD DILI  ATT INDUCED 
DECOMPENSATION 
ALCOHOL 
AND HBV 
ACLF 
REGIME CHANGE 
FOR TB 
CHRONIC CPMZ 
INDUCED  ATT 
ACLF 
0 1 3 1 1 
  2 DIED  1-DIED 
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12.Persistent DILI 
% of Persistent DILI was 18.1%. According to this study 2 patients had  
persistent high  LFT values  after ATT, in spite of their baseline LFT being 
normal.  2 out 11 patients had persistent DILI.  
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13.CLINICAL PROFILE IN DEATHS DUE TO DILI IN GROUP 1: 
33% presenting with jaundice died 
50% presenting with ascites died 
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14.Group 2: 
50% patients presenting with jaundice died due to DILI  
50% patients presenting with ascites died. 
50% patients with pedal edema died 
40% patients presenting with encephalopathy died. 
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15.AGE WISE DISTRIBUTION OF DILI in Group 2: 
 Age Group distribution of DILI: 
Age group DILI 
recovered 
DILI not 
recovered 
Odds ratio 95% CI 
<50 years 4 3 Not possible  
≥50 years 3 0   
 
There was no stastical significance between the two age groups <50 years and 
>50 years among patients with DILI .  
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ESTABLISHING  DIAGNOSIS  OF TB IN STUDY GROUPS: 
Except  for 2 cases who were started on Empirical ATT all cases were 
adequately proven of tuberculosis  and started on ATT from our Chest clinic 
and DOTS centre. The other Cases DILI referred to us were also adequately 
proven to diagnose tuberculosis. 
In the demographic profile, among Group 1 patients , 3 patients had TB ascites 
proven by lab analysis.  All of them had normal baseline LFT and were ruled out 
of underlying CLD with the protocol investigations. 
In group 2, patients  ie, with altered baseline LFT , 4 patients had mixed ascites 
and 4 patients had TB ascites all of which were adequately proven .  
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TO CONCLUDE , among group 1, 17  had hepatic adaptation, while patients  still 
continued same regime. Five had Enzymes > 5ULN, at third week. They  were 
changed over to Non DOTS Non hepatotoxic SEOregime (Streptomycin, 
Etambutol,  Ofloxacin) .  Diabetes , Female gender was a significant comorbid 
factor . One Chronic HBV infected individual with low virology and normal 
baseline LFT  had ,ALT>3, continued same with  enzymes <3ULN till 
completion.3 had ACLF (One diabetic) & of them 1 died. 
 
                                                                                                           
         
                             
   
 
 
 
 
 
 
 
80 
 
                       
                                                                               
 
 
 
 
 
 
 
                   DISCUSSION                                              
                                                                                
 
 
 
 
 
 
 
 
 
 
81 
 
 
 
                                                                                 DISCUSSION 
The incidence of overall DILI in total cases is 11.2%. The incidence of DILI in 
group 1 is 9.4%. The incidence of DILI in Group 2 is 20.6%.This shows the higher 
incidence of DILI in patients with underlying liver diseases. 
This incidence at our institute is in par with other studies like, Andrade AJ et 
al38,  
According to Harshad Devar Bhavi39, many of the ATT DILI is under reported 
and the overall incidence in the population is unknown. 
Kapanoff, D.E, et al40 have studied on the Incidence of INH related Hepatitis 
and and found incidence of ATT DILI ranging from 5 -33%,  
 According to American Thoracic Society Guidelines the overall incidence of 
ATT DILI is 5 to 33%. 
The higher incidence of ATT induced hepatotoxicity is in par with Rakesh     
Tandon’s article where he says there is an increased incidence of DILI and 
lower completion rates of ATT in Patients with liver disease. He refers 
“Westphal, et al –and and “Keiding et al41.   
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This is also in par with Deepak Amrapurkar’s “Prescribing medications in 
patients with CLD”. 
According to DILI by Naga Chalasani42, –women have a slightly higher risk of 
liver injury due to “certain medications” and not “all cause DILI”. This study has 
also come out with similar results in Group 1 , where the incidence is 55.4% in 
females, while it  is 44.6% in males. This is in par with Kaplowitz.n, where it is 
stated that females with high CD4 count have Nevirapine toxicity. 
A preliminary report from DILI Network (DILIN), states that diabetics have 
increased risk of all cause DILI and it was independently associated with 
severity of DILI. Diabetics have more severe disease outcome in DILI with an 
ODDS RATIO of2.69; CI=1.14-6.45. 
The ODDS RATIO in this present study is 3.5; (95%CI 0145-84.4). 
  Naga Chalasani, has brought out this  poor outcome in diabetics, in The recent 
American college of Gastro Enterology Guidelines ,Idiosyncratic DILI,  2014.  
The ODDS ratio in Group 2 was not applicable since there were no Diabetic 
deaths. 
The Mortality rates in various studies have shown higher rates in TB DILI, from  
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More serious liver disease like ALF ranges from 1-3% is as quoted by F Smink43 
Risk factors of acute hepatic failure during ATT, Netherlands Journal of 
Medicine, in the study done by “Girling DJ. The rate of mortality in this study is 
27.2% in Group 1 and 50% in Group 2. This shows almost twice the mortality in 
patients with altered baseline LFT or underlying liver disease s normal 
individuals. 
As established in various studies Females had a higher mortality rate and 
severity with the onset of DILI. The mortality rate in females in group 1 is twice 
high as in males. 
The ODDS ratio of mortality in DILI between Male and Female deaths is 0.5; 
(95%CI 0.81-7.94). 
The studies by Ormerod et al 49 and Shakaya R, et al50, are in par with these 
results. 
“Kumar & Shalimar et al51, reported ATT as the leading cause of Drug induced 
Acute Liver failure with a mortality rate of 67% in   ATT ALF. This holds true in 
our study where the one patient with DIALF died (50% mortality in DIALF). 
Harshad Devar Bhavi52 had found that ATT ALF is also the common cause of 
DIALF in South India, with concordance of 97% mortality. 
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S.K.Sarin, has stated that “Hepatotoxic Drugs and complementary and 
alternative medicines are an important cause of ACLF in Asia Pacific Region.,as 
proved by studies like Duseja56, Y K Chawla, R K Dhiman,56 - Non hepatic insults 
are common in ACLF. 
ACLF has high 28 day mortality, of 50- 90%, as in various studies, one by Jalan57 
et al, and the other by S K Sarin, et al. 
The mortality rate in  28 day mortality in ACLF  in this study was  66.4% in 
Group 1, and  33.4%in Group 2.The close monitoring and effective ways of 
follow up of their underlying liver disease, watch for adverse reactions on 
prescribing special drugs and better compliance of drugs  prevented DIACLF 
mortality in Group 2. 
Hepatic Adaptation was 6.9% in Group 1 and 48.3% in Group 2.This shows the 
adequate hepatic reserve in patients with underlying liver disease, and the 
capacity to detoxify drugs. 
Hepatic adaptation had no predictive value in DILI in this study and most DILI 
were unpredictable, idiosyncratic reactions. 
The incidence of persistent DILI was 28%, who had persistent mild enzyme 
raise <3ULN, after the 6 months course, on follow up of 6 months.  
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Alcohol was found to be the most important confounding factor in persistant 
DILI. 
Concomitant  Hepatotoxic drugs play an important role in prescribing ATT .The 
long term effects ,cumulative or dose dependant ,may be silent , causing 
hyperacute or acute course of decompensation and short latency period for HE 
and death on addition of an acute insult. One patient was on  4 years 
Methotrexate for Rheumatoid arthritis and another was on chlorpromazine, 
both had a FHF and succumbed in 
<1 week of ATT. “Progression to  chronicity is seen 5-10% of DILI and more in 
cholestsatic /mixed pattern injury , in a study done by Andrae RJ et al. The 
cumulative hepatoxicity of methotrexate , may silent with periportal fibrosis  
and Macrovesicular steatosis and  may be exacerbated by alcohol or ATT,  to 
severe hepatocellular necrosis.This is described by Langman G, NASH in MTX  
liver injury . 
Prolonged Cholestastic hepatitis   may persist in Chlorpromazine ,with   severe 
ductopenia, the vanishing bile duct syndrome which may lead to biliary 
cirrhosis ,like Primary biliary cirrhosis.  
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                                                                                           CONCLUSION 
1. There is increased incidence of DILI in patients with                                               
Altered   Baseline LFT values. 
 
2. Females with Normal baseline LFT have higher Odds for DILI deaths than  
     Males. 
 
3. Diabetics with Normal baseline LFT, have higher Odds for DILI deaths than    
     Non Diabetics 
 
4. The patients with altered baseline LFT values have higher mortality with ATT  
 
5. Periodic monitoring of LFT prevents mortality in DILI. 
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LIMITATIONS OF THIS STUDY: 
1. Smaller sample size 
2. DILI needs a larger population size to extrapolate the risk according to HY’S 
law 
3. Management aspects of acute liver failure or acute on chronic liver failure 
are not analysed. 
4. Severe complications of DILI need more analysis pertaining to risk factors 
and inciting events. 
5. The tropism for hepatotropic viruses (ACUTE A, E, C) in DILI are not 
established 
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ABREVIATION 
1. DILI – DRUG INDUCED LIVER INJURY 
2. ALF-ACUTE LIVER FAILURE 
3. ACLF-ACUTE ON CHRONIC LIVER FAILURE 
4. ATT- ANTI TUBERCULOUS TREATMENT 
5. DCLD-DECOMPENSATED CHRONIC LIVER DISEASE 
6. HBV- HEPATITIS B VIRUS 
7. P- PULMONARY 
8. EP-EXTRA. PULMONARY 
. 
6. Genetic causes of susceptibility not established 
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 PROFORMA 
NAME :                                                           AGE/SEX:                                         DDHD NO: 
 
DOA:                                                       RNTCP NO:                                                    
 
HISTORY: 
YELLOWISH DISCOLORATION :                     PRURITIS:                                       PALE STOOLS: 
FEVER:                                                               ANOREXIA:                                     NAUSEA/VOMITING: 
LOA:                                                                   LOSS OF WT:                                   HYPERPIGMENTATION: 
 ABD DISTENSION:                                            ABD PAIN:                                      COUGH/ EXPECTORATION: 
  PAST HISTORY: 
JAUNDICE:                                                        BLOOD TRANSFUSION:                  TATOOING: 
DM:                                                                    SHT:             TB: 
PERSONAL HISTORY: 
Iv DRUG ABUSE:                                               DRUG INTAKE:                                 ALCOHOL: 
FAMILY HISTORY:    
 
GENERAL EXAMINATION: 
CONSCIOUS/ORIENTED: PALLOR:                                          ICTERUS: 
CYANOSIS:                                                           CLUBBING:                                      EDEMA: 
LYMPHADENOPATHY:                                       SCRATCH MARKS:                           
OTHER SIGNS: 
VITALS:                       HT:                                      WT:                            BMI: 
PULSE:                        BP:                                     TEMP:                        URINE OUTPUT: 
SYSTEMIC EXAMINATION: 
P/A: 
 RS  : 
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OTHER SYSTEMS: 
CVS:                                                                                                                                   CNS: 
INVESTIGATIONS:                                         
Hb  :       BT:                             CT:                                       Pl COUNT:                           PT: T        C       INR: 
ESR:                                     TC :                                                        DC:P          L                 E            M 
RBS  :                                     UREA :                                             Sr. CREATININE :  
BT:                             CT:                                       Pl COUNT:                           PT: T        C       INR: 
 
VIRAL MARKERS: 
        HbsAg:                                          AntiHCV:                                  HIV:                                         
CHEST X RAY: 
USG ABDOMEN: 
SPUTUM AFB: 
OTHRES : 
TREATMENT: 
DURATION : 
              
 
                    
DATE 
        
TOTAL 
BR 
        
DIRECT         
I.D         
SGOT         
SGPO         
ALP         
GGT         
T. PRO         
ALB         
GLO         
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NAME AGE/SEX SEX TB -PULM/EP CO-MOR CBC HB USG ABD REGIME S.BIL DIR SGOT SGPT SAP STP ALB INR BASELINE LIVER DIS JAUNDICE ASITES HE PE FEVER ALCOHOL HEP B,C CONCOMITANT DRUGS H.ADAPTATION LATENCY J/E INTERVAL DILI Y/N
SARAVANA MUTHU 42 M DISSEMINATED DM 9100 11 ASCITES HRE 1.4 0.7 58 27 50 6 2.3 1.1 CTP B N Y Y Y N N POS INSULIN N 2 WKS 2 WEEKS Y- DIACLF-RECOVERED 
AMUDHAVANAN 60 M DISSEMINATED DM 1200 10.4 ASCITES HEC 1.7 0.9 160 40 97 6.2 2.5 1.2 CTP B Y Y N Y N Y NEG DIURETICS,PPNL Y NA NA N
ARUMUGAM 44 M PT DM 10200 10 ASCITES HEO 1.5 0.8 76 78 142 6.4 3.1 1.1 CTP B Y Y Y N N Y NEG DIURETICS,PPNL N NA NA Y  - REGIME CHANGED
VENKATESAN 28 M  DISSEMINATED N 6500 11.3 ASCITES HRE 2 0.3 45 54 322 6.2 2.5 1.5 CTP B Y Y Y Y N Y NEG DIURETICS,PPNL N 1 WK 1 WK Y- DIACLF-RECOVERD
RAVI 54 M MIXED ASCITES N 8900 10.1 ASCITES SHE 1.4 0.7 79 20 52 6.1 3.1 1.2 CTP B N Y N N N Y NEG NO Y NA NA N
DHAYALAN 45 M PT N 9900 11.2 FATTYLIVER SHE 0.4 0.3 33 44 112 6.9 3.6 1.2 UNDIAGNOSED CHB Y Y N N N Y  CHB TENOFOVIR N 10 DAYS NA Y- ATT INDUCED DECOMP 
SURESH BABU 45 M MIXED ASCITES DM 10200 8.7 ASITES/CIRRHOSIS HRE 1.3 0.5 54 35 187 6.8 2.5 1.1 CLD /PANC. ASCITES N Y N Y Y Y NEG NO DEFAULTED DEFAULTED DEFAULTED
SETTU 40 M  TB ASCITES N 9000 9.6 ASCITES HRE 2.5 1 89 36 462 7.9 4.1 1.1 CTP B / TB ASCITES N Y N N N Y NEG NO Y NA NA N
VENKATESAN 38 M BIL PT N 9300 10.6 ASCITES HRE 1.8 1 59 27 127 5.8 2.8 1.2 CTP B N Y N N N N NEG DIURETICS,PPNL N NA NA N
SURESH 35 M PT N 7800 11.8 ASCITES HEO 1.5 0.9 67 54 112 6.3 3.1 1.1 CTP B N Y N Y N Y NEG DIURETICS N NA NA N
MOHAN 55 M PT/TB ASCITES N 8900 10 ASCITES HEO 1.3 0.5 65 45 105 5.4 3 1.2 CTP B N Y N Y N Y CHB DIURETICS,PPNL Y NA NA N
CHOCKALINGAM 57 M PT N 7900 9.1 ASCITES HEO 1.2 0.6 47 42 180 6.2 3 1.1 CTP B N Y N Y N Y NEG DIURETICS,PPNL Y NA NA N
BALAKRISHNAN 55 M PT N 9600 8.4 ASCITES HRE 1.3 0.5 142 54 112 6.1 2.5 1.2 CTP B N Y N Y N Y NEG DIURETICS N NA NA N
THIAGARAJAN 51 M PT N 7600 7.5 ASCITES HRE 2.4 1.5 93 89 143 6.3 3.2 1.2 CTP B N Y N Y N Y NEG DIURETICS,PPNL Y NA NA N
SUBRAMANI    68 M PT N 9600 10 ASCITES/CIRRHOSIS HRE 1.4 0.6 57 26 102 7.2 3.5 1.2 CTP B N Y N Y N Y NEG DIURETICS Y NA NA N
DHEENADHAYALAN 53 M PT N 10200 8.5 ASCITES/PT SHE 1.5 1.2 66 94 289 6.4 3.2 1.3 CTP B N Y N Y N Y NEG DIURETICS Y NA NA N
SUBRAMANIAN 32 M TB ASCITES N 9800 9  ACITES HRE 1.2 0.8 34 25 227 6.9 3.7 1.1 CTP B/TB ASCITES N Y N Y Y Y NEG NO N NA NA N
RAVI 54 M MIXED ASCITES N 6800 12 ASC/CIRR HRE 1.4 0.7 79 20 52 6.1 3.2 1.1 CTP B N Y N N N Y NEG DIURETICS,PPNL Y NA NA N
SUBRAMANI 45 M PT N 14100 9.9 N-STUDY HRE 0.7 0.3 53 41 6.3 3.5 3.1 1.1 CTP B N N N N N Y NEG DIURETICS,PPNL N NA NA N
SIVA 22 M PT N 7800 11.2 N-STUDY HRZE 1.9 0.8 42 21 165 6.8 3.8 1.1 CHB N N N N N Y POS NO N NA NA N
SURESH 25 M PT N 9800 11.5 N-STUDY HRZE 0.8 0.5 55 84 160 7.4 4.6 1.2 CLD N N N N N Y NEG NO Y NA NA N
BALAMURUGAN 35 M PT N 8900 9.6 N-STUDY HRZE 0.6 59 38 62 7.2 3.4 1.1 CLD N N N N N Y NEG NO Y NA NA N
PARTHIBAN 39 M PT N 6300 9.7 FATTYLIVER HRZE 1.2 1.4 0.9 131 68 6.2 3.8 1.2 CLD N N N N N Y NEG NO Y NA NA N
VIJAYAKUMAR 35 M PT N 9200 10.1 HEPATOMEG HRE 1.2 0.6 65 42 209 7.3 3.6 1.1 CLD N N N N N Y NEG NO N NA NA N
MUTHURAMALINGAM 51 M PT N 7600 11.3 HEPATOMEG HRZE 0.8 0.5 90 204 132 7.2 3.4 1.2 CLD N N N N N Y NEG NO Y NA NA N
VENKATESAN 44 M PT ICTHYOSIS XEROSIS8900 9 ASCITES HRE 1.7 0.5 41 23 179 7.4 3.3 1.3 CLD Y Y Y Y N Y NEG DIU, PPNL N 1 WEEK 2DAYS Y-DICLF -DIED
GOWRI 61 F MIXED ASCITES N 8800 9 ASCITES HRE 1.9 1 80 42 402 6.8 3.5 1.2 DCLD?NASH N N N N N N NEG PPNL,DIUTETICS Y NA NA N
SHAJAHAN 40 M PT DM 6200 12 FATTYLIVER HRE 0.7 0.4 51 20 350 6.4 3.5 1 CLD N N N N N Y NEG OHAS,INSULIN N NA NA N
ARULRAJ 54 M TB ASCITES N 9400 10.3 FATTY LIVER HRZE 1.2 0.8 34 41 214 6.8 3.6 1.4 ?CHRONIC DILI N Y Y Y Y N NEG CHLORPROMAZINE N 1WK 1WK Y - ?CHR.DILI -DIACLF-DIED
NAME AGE/SEX TB - P/EP CO-MORB CBC Hb USG ABD S.BIL DIRECT SGOT SGPT SAP STP S.ALB INR JAUNDICE ASCITES HE PE FEVER HEP B,C CONCOMITANT DRUGSADAPTATION LATENCY HEP A,E J/HE INTERVAL DILI Y/N
MAHALINGAM 44 M PT N 7700 13.2 N- STUDY 0.5 0.2 36 21 105 8.2 4.2 1 N N N N N NEG NO YES NA NA N
SAROJA 65 M PT N 10250 9.2 N- STUDY 0.7 0.3 19 12 112 8.2 4 N N N N N NEG NO NO NA NA N
RAJESH 21 M PT N 10200 9.8 N- STUDY 0.8 0.3 23 28 157 7.2 4 N N N N N NEG NO NO NA NA N
SASIKALA 50 F L.PL EFF N 9800 11.2 L- PL EFF 0.6 0.4 24 23 776 8.2 3.9 0.9 N N N N N NEG NO YES NA NA N
KAVIMALA 23 F PT N 8800 10.8 N- STUDY 1.1 0.8 44 59 109 8.6 3.9 1.1 N N N N N NEG NO YES NA NA N
BALARAMAN 54 M PT N 8900 12.8 FATTY LIVER 3.9 2.1 29 647 136 7.1 3.6 0.9 Y N N N N NEG OHAs NO 10DAYS NEG NA Y- RECOVERED
HARIBABU 43 M PT N 8900 11.2 N-STUDY 1 0.7 36 28 102 7.7 3.9 1.2 N N N N N NEG NO YES NA NA N
MANIGANDAN 23 M TB ASCITES N 9300 12 ASCITES 0.9 0.4 29 15 103 7.3 3.5 1.1 N N N N N NEG NO YES NA NA N
CHANDRASEKAR 47 M PT N 10,700 12.4 N-STUDY 0.7 0.4 17 19 109 7.3 3.4 N N N N N NEG NO NO NA NA N
KRISHNAMOORTHY 68 F PT N 10,100 10.8 N- STUDY 0.9 0.3 19 17 104 7.2 3.2 N N N N N NEG NO NO NA NA N
DURGA DEVI 27 F TB  LN N 7800 12.1 N-STUDY 0.8 0.3 18 19 102 7.3 3.5 N N N N N NEG NO NO NA NA N
CHANDRASEKAR 47 M PT N 7900 11.2 N-STUDY 0.9 0.5 19 21 105 7.5 3.9 N N N N N NEG NO NO NA NA N
DHANALAKSHMI 35 F PTT N 8700 10.2 N-STUDY 0.6 0.4 18 23 105 7.4 3.5 N N N N N NEG NO NO NA NA N
ELUMALAI 66 M PT N 7900 12.1 N-STUDY 0.6 0.4 23 22 104 7.4 3.4 N N N N N NEG NO NO NA NA N
ANUSHYA 45 F PT N 7600 11.1 L PL EFF 0.7 0.5 24 25 101 7.2 3.4 N N N N N NEG NO NO NA NA N
CHINNAIYAH 60 M PT N 9800 10.9 N-STUDY 0.8 0.5 22 30 143 6.5 3.3 N N N N N NEG NO NO NA NA N
DEEPA RANI 34 F PT N 9900 11.1 N-STUDY 0.8 0.3 31 37 104 6.9 3.6 1.1 N N N N N NEG NO YES NA NA N
AMUDHA 28 F PT N 11000 10.1 N-STUDY 0.9 0.7 26 27 106 6.7 3.5 1 N N N N N NEG NO YES NA NA N
SANGAMITHRAN 45 M PT N 8700 10.6 N-STUDY 0.8 0.3 22 25 55 6.9 3.4 N N N N N NEG NO NO NA NA N
ANUSHYA 65 F PT DM 8900 11.3 FATTY LIVER 4.3 3.2 89 93 420 6.5 3.2 Y N N N N NEG OHAS NO 1 MONTH NEG NA Y/R
KANDASAMY 34 M L .PL EFF N 8700 11.5 N-STUDY 0.9 0.5 24 28 64 6.1 3.6 N N N N N NEG NO NO NA NA N
NIRMALA 45 F TB LN N 9800 10.5 N-STUDY 1.1 0.5 10 16 73 6.3 3.7 N N N N N NEG NO NO NA NA N
NIRMALA 32 F PT N 9700 10.5 N-STUDY 0.7 0.4 42 19 124 6.2 3.1 N N N N N NEG NO NO NA NA N
BOOPALAN 28 M PT N 8900 11.4 N-STUDY 0.6 0.3 22 25 102 6.4 3 N N N N N NEG NO NO NA NA N
GEETHA 25 M PT N 9300 12.1 N-STUDY 0.7 0.3 19 21 57 6.4 3 N N N N N NEG NO NO NA NA N
DEEPA 41 F PT N 7600 11.2 N-STUDY 0.8 0.4 18 23 58 6.3 4 N N N N N NEG NO NO NA NA N
ZAIRA BEGUM 40 F PT N 7800 12 N-STUDY 1 0.5 27 17 72 6.9 3.6 N N N N N NEG NO NO NA NA N
LAKSHMI 33 F TB LN N 4100 13 N-STUDY 0.7 0.4 23 16 108 6.4 4.3 N N N N N NEG NO NO NA NA N
VELAN 35 F PT N 6300 11.2 N-STUDY 0.9 0.5 22 17 109 6.2 4.1 N N N N N NEG NO NO NA NA N
POORNIMA 24 F PL. EFF N 7800 12.1 N-STUDY 0.8 0.7 24 18 102 6.5 4.1 N N N N N NEG NO NO NA NA N
MUMTAJ BEGUM 25 F PT N 9800 11.4 N-STUDY 0.9 0.6 22 21 101 6.5 3.2 N N N N N NEG NO NO NA NA N
JAYPAUL 56 M PT N 10100 11.5 N-STUDY 0.4 0.2 24 15 74 6.4 3.6 N N N N N NEG NO NO NA NA N
SOWMYA 15 F PT N 7900 10.4 N-STUDY 0.7 0.5 25 33 78 6.2 3.3 N N N N N NEG NO NO NA NA N
KUSCHITRE 31 F PT N 9500 11.2 N-STUDY 0.8 0.6 26 22 76 6.1 3.1 N N N N N NEG NO NO NA NA N
RENUKHA 23 F PT N 9600 9.9 N-STUDY 0.9 0.4 37 32 8 6.3 3.1 N N N N N NEG NO NO NA NA N
KALAISELVI 45 F PT DM 11800 11 FATTY LIVER 8.9 5.6 560 408 182 7.2 3.6 1.5 N Y Y N N NEG OHA,ANTI HT NO 4 MTHS HEV 1 WK Y- NR
VARUNKUMAR 33 M PT N 10,700 11.2 N-STUDY 3.4 2 293 245 144 7.6 4.1 1.3 N Y N N N NEG OHAS NO 8MTHS NEG NA Y- R
WAHEEDHA 46 F PT N 7800 12 N-STUDY O.5 0.3 16 16 100 6.5 4.3 N N N N N NEG OHAS NO NA NA N
BHUVANESWARI 19 F TB ASCITES N 11000 10.1 ASCITES 0.6 0.4 15 13 71 7.1 3.8 N Y N N N NEG NO NO NA NA N
HAJIRA BEE 54 M PT N 11700 10.6 N-STUDY 0.7 0.4 39 30 166 6.5 3.3 N N N N N NEG NO NO NA NA N
PUNITHAMARY 44 F PT N 10100 9.5 N-STUDY 1.5 1.1 172 60 178 6.2 3.4 Y N N N N NEG NO NO NA NA N
MANIKANDAN 18 M PT N 9400 11.2 N-STUDY 0.9 0.6 59 127 158 7.2 3.9 N N N N N NEG NO YES NA NA N
BABU 52 M PT DM 6290 12.4 N-STUDY 0.4 0.3 17 15 99 7.4 3.3 N N N N N NEG OHAS NO NA NA N
ANBANANDHAN 47 M PT N 7120 10.2 N-STUDY 0.3 0.2 13 16 103 7.2 4.2 N N N N N NEG NO NO NA NA N
JEYAKUMAR 58 M PT N 12640 8.2 N-STUDY 0.3 0.2 20 25 102 7.3 3.6 N N N N N NEG NO NO NA NA N
RAYAPPAN 49 M PT N 7700 9.2 N-STUDY 0.6 0.3 25 23 99 6.9 3.8 N N N N N NEG NO NO NA NA N
RESHMA 18 F PT N 5460 9.5 N-STUDY 0.4 0.2 21 24 93 6.4 3.3 N N N N N NEG NO NO NA NA N
SAROJA 50 F TB LN N 10100 11.8 N-STUDY 0.7 0.4 24 29 56 6.9 3.4 N N N N N NEG NO NO NA NA N
THIRUVENKATAM 48 M PT N 9960 11.6 N-STUDY 1.1 0.7 28 24 78 6.3 3.7 N N N N N NEG NO NO NA NA N  
MOHAMMED YUSUF 45 M PT DM 6840 11.2 N-STUDY 0.6 0.4 18 25 98 6.8 3.2 N N N N N NEG NO NO NA NA N
SUBRAMANI 45 M PT N 14100 9.9 N-STUDY 0.8 0.3 24 27 76 7.1 3 N N N N N NEG NO NO NA NA N
ANJARIAH 32 M PT DM 14050 8.9 N-STUDY 0.7 0.5 21 29 67 3.5 3.5 N N N N N NEG NO NO NA NA N
KUMAR 60 M PT DM 11400 10.6 N-STUDY 0.8 0.5 22 13 78 7.5 3.5 N N N N N NEG NO NO NA NA N
SIVAKUMAR 32 M PT N 9380 14.4 N-STUDY 0.6 0.4 12 25 98 6.8 3.2 N N N N N NEG NO NO NA NA N
RAJESHWARI 29 F PT N 7290 11.7 N-STUDY 0.4 0.3 28 38 77 7.2 3.9 N N N N N NEG NO NO NA NA N
PARAMESHWARI 12 F PT N 14,320 10.7 N-STUDY 0.5 0.3 36 38 89 7.9 3.5 N N N N N NEG NO NO NA NA N
LIDYA 55 F PT N 6700 12.8 N-STUDY 0.7 0.4 28 35 120 6.4 3.7 N N N N N NEG NO NO NA NA N
SARAWATHY 43 F PT N 5364 8.1 N-STUDY 0.6 0.4 27 32 107 6.6 3.4 N N N N N NEG NO NO NA NA N
KARTHICK 25 M PT N 4700 8.1 N-STUDY 0.3 0.2 13 12 67 6.4 3.2 N N N N N NEG NO NO NA NA N
KARUNANITHI 40 M TB ASCITES N 9800 10.1 ASCITES 0.7 0.3 98 110 666 6.7 3.7 Y N N N N NEG NO NO NA NEG NA Y/R
NAME AGE SEX TB-  PULM/EP CO-MOR TC Hb USG ABD S.BIL D.BIL SGOT SGPT SAP STP ALB JAUND ASCITES PE HE FEVER HEP B,C CONCOMITANT DRUGS H.ADAPATATION HEP A,E JE INT DILI Y/N
ANGEL MARY 34 F TB LN N 3.2 Y N N N N NEG NO NO NEG 2WEEKS Y- R
KRISHNAMURTHY 68 M PT N 9700 11.2 N-STUDY 0.7 0.5 23 33 110 7.4 3.7 N N N N N NEG NO NO NA N
SELVAKUMAR 22 M PT N 9560 11.2 N-STUDY 0.8 0.3 28 41 101 7.4 3.5 N N N N N NEG NO NO NA N
SAFIQ 46 M TB LN N 6500 13.1 N-STUDY 0.9 0.6 27 29 121 7.1 3.2 N N N N N NEG NO NO NA N
MURUGAN 49 M PT N 9100 12 N-STUDY 0.5 0.3 21 27 105 7.5 3.5 N N N N N NEG NO NO NA N
SEKAR 53 M PT N 9500 9.4 N-STUDY 0.5 0.4 26 10 98 7.3 3.2 N N N N N NEG NO NO NA N
SATHYANARAYANAN 51 M PT N 11200 9.3 N-STUDY 0.6 0.3 35 20 89 7.8 4.1 N N N N N NEG NO NO NA N
BASKARAN 43 M PT N 9170 11.4 N-STUDY 0.8 0.3 14 24 112 8 4.1 N N N N N NEG NO NO NA N
ANBARASU 34 M PT N 8840 12.3 N-STUDY 0.4 0.2 21 19 97 7.4 3.5 N N N N N NEG NO NO NA N
VENKAMMAL 40 F PT N 4650 9.1 N-STUDY 0.3 0.1 31 37 96 7.5 3.6 N N N N N NEG NO NO NA N
SRINIVASAN 45 M PT N 9600 13.6 N-STUDY 1 0.4 41 24 95 7.8 3.7 N N N N N NEG NO NO NA N
BALAMURUGAN 27 M PT N 8310 12.2 N-STUDY 1.1 0.5 31 34 88 7.5 3.5 N N N N N NEG NO NO NA N
HARI 18 M PT N 4900 11.3 N-STUDY 0.9 0.4 32 34 89 7.8 3.6 N N N N N NEG NO NO NA N
GOVINDASAMY 60 M PT N 5600 12.1 N-STUDY 0.7 0.4 33 41 93 7.4 3.7 N N N N N NEG NO NO NA N
NANDHINI 16 F PT N 7700 11.2 FATTY LIV 0.6 0.3 25 19 87 7.3 3.2 N N N N N NEG NO NO NA N
NEELAKANDAN 45 M PT N 12780 10.8 N-STUDY 0.6 0.3 39 27 97 7.3 3.5 N N N N N NEG NO NO NA N
NAGAMMAL 52 F PT N 7600 11.6 N-STUDY 0.4 0.2 17 18 103 7.5 4.1 N N N N N NEG NO NO NA N
ARUUGAM 63 M Y Y Y Y Y NEG NO NO HEP A + 1WK Y/NR
VALARMATHI 51 F PT N 7180 11.2 N-STUDY 0.6 0.3 17 19 102 7.2 3.2 N N N N N NEG NO NO NA N
SUBRAMANI 70 M PT DM 11400 12.9 FATTY LIV 1.1 0.8 25 23 80 7.3 3.6 N N N N N NEG OHAS NO NA N
HERCULES 48 M PT N 10420 11.7 N-STUDY 0.6 0.3 20 10 89 7.9 3.2 N N N N N NEG NO NO NA N
MOORTHY 45 M PT N 7100 10.7 FATTY LIV 0.9 0.5 33 34 98 7.4 3.5 N N N N N NEG NO NO NA N
BALARAMAN 60 M PT N 9140 10.3 N-STUDY 0.7 0.3 19 23 99 7.3 3.5 N N N N N NEG NO NO NA N
LAKSHMI 53 F PT N 8120 10.8 FATTY LIV 1 0.5 31 27 98 7.9 3.4 N N N N N NEG NO NO NA N
VIJAYACHANDRAN 34 M PT N 6080 12.2 FATTY LIV 0.9 0.7 44 40 79 7.2 3.2 N N N N N NEG NO NO NA N
RAVANAMMAL 46 F PT DM 7780 10.7 FATTY LIV 0.9 0.4 16 30 59 7.4 3.2 N N N N N NEG OHAS NO NA N
NARMADA 32 F PT N 5660 8.8 N-STUDY 1 0.4 16 30 78 7.2 3.1 N N N N N NEG NO NO NA N
SAROJA 65 F PT N 10250 9.2 FATTY LIV 1 0.6 19 12 89 7.3 3.1 N N N N N NEG NO NO NA N
POOJA 16 F TB LN N 8200 6.9 N-STUDY 3.6 2.9 152 167 1156 6.8 3.8 Y N N N N NEG NO NO NEG NA Y/R
ARUL 40 M PT N 8920 13.3 FATTY LIV 0.8 0.5 15 12 89 7.3 3.5 N N N N N NEG NO NO NA N
SIGAMANI 54 M PT N 9600 9.2 N-STUDY 0.7 0.3 34 26 132 6.5 3.4 N N N N N NEG NO NO NA N
RAJAKUMARI 19 F TB LN N 6100 11.8 N-STUDY 0.8 0.4 18 12 43 6.9 3.9 N N N N N NEG NO NO NA N
THILAGAM 58 F PT DM 6200 11 FATTY LIV 0.5 0.3 18 23 98 7.4 3.8 N N N N N NEG OHAS NO NA N
UMA MAHESHWARI 23 F EMP ATT  WILSONS & SLE 7600 N-STUDY 4.5 3.1 356 235 486 6.7 3.9 Y N N N Y NEG NO NO NA Y /R
CHARLES 59 M PT DM 7100 10.4 N-STUDY 0.7 0.5 21 29 160 7.5 3.6 Y N N N N NEG OHAS NO NA N
MOHANA 39 F PT N 7460 13.2 N-STUDY 1.2 1 26 33 151 7.3 3.7 N N N N N NEG NO NO NA N
KAVITHA 32 F TB LN N 8330 10.5 FATTY LIV 0.7 0.6 21 14 65 6.3 3.9 N N N N N NEG NO NO NA N
JAMUNA RANI 45 F TB SPINE RA 9140 12.9 FATTY LIVER 12..5 10 348 235 765 6.5 3.1 Y Y Y Y Y NEG MTX NO NAG 1 WK Y/NR
INDRANI 60 F PT DM 9800 9 FATTY LIV 0.4 0.9 12 18 94 8.2 4.1 N N N N N NEG OHAS NO NA N
SIVAKUMAR 25 M TB LN N 6460 11.6 N-STUDY 0.6 1 22 37 102 7 3.8 N N N N N NEG NO NO NA N
MAHALAKSHMI 26 F PL EFF N 4200 10.6 FATTY LIV 0.9 0.8 43 24 124 8.1 3.9 N N N N N NEG NO NO NA N
RANI 70 F PT DM 8150 11.4 FATTY LIV 0.5 0.3 16 18 130 7.5 4.2 N N N N N NEG NO NO NA N
KRISHNAN 18 M TB LN N 8440 12.1 N-STUDY 0.6 0.3 24 19 79 6.4 3.4 N N N N N NEG NO NO NA N
LILLY 33 F TB LN N 8200 11 FATTY LIV 0.4 1 15 18 52 7.1 3.7 N N N N N NEG NO NO NA N
TAMILSELVI 42 F TB LN N 9800 12 N-STUDY 0.9 0.8 87 54 102 7.3 3.1 N N N N N NEG NO NO NA N
MOHAN 50 M PT DM 11200 11.2 FATTY LIV 0.8 0 30 27 65 6.3 3.3 N N N N N NEG OHAS NO NA N
KALIMUTHU 67 M PL EFF N 8200 12 FATTY LIV 0.7 0.6 48 28 69 6.5 3.6 N N N N N NEG NO NO NA N
VASANTHAKUMAR 17 M PL EFF N 9800 10.4 N-STUDY 0.7 0.6 22 18 54 5.6 3.4 N N N N N NEG NO NO NA N
VENKATTAIAH 64 M PT DM 4790 7.5 FATTY LIV 0.9 0.7 20 16 72 7.3 3.7 N N N N N NEG NO NO NA N
BALAMURUGAN 35 M PT N 12100 10.6 N-STUDY 0.6 0.4 29 22 45 7.5 3.7 N N N N N NEG NO NO NA N
GAYATHRI 23 F TB SPINE N 7800 9.6 N-STUDY 1.2 0.7 19 17 39 7.6 3.6 N N N N N NEG NO NO NA N
PRAVEENA 18 F IC TB- EMP N 8900 9.4 N-STUDY 0.9 0.6 18 22 76 7.8 3.7 N N N N N NEG NO NO NA N
THIRUMOORTHY 45 M PT N 9500 10.4 FATTY LIV 1.2 0.4 26 34 78 7.3 3.5 N N N N N NEG NO NO NA N
MOSES 49 M PT N 880 10.5 FATTY LIV 2.4 0.9 50 132 795 7.5 2.9 Y N N N N NEG NO NO NA Y/R
USHA 15 IC TB N 6700 10.6 N-STUDY 0.9 0.5 28 22 6 6.3 3.3 N N N N N NEG NO NO NA N
KALAISELVI 35 F IC TB N 9800 11.1 N-STUDY 0.8 0.6 48 62 156 7.1 3.1 N N N N N NEG NO NO NA N
